Democritus University of Thrace (DUTH)
Κυτταρικοί και μοριακοί μεσολαβητές στην ανοσοθρόμβωση και στην ανοσοϊνωση
Abstract
dc:descriptionImmunothrombosis and immunofibrosis are mechanisms associated with the pathogenesis of a wide range of disorders, including infections, inflammatory, autoimmune, and cardiovascular/metabolic diseases, affecting a large number of patients worldwide. They are functionally linked to common molecular pathways and cellular populations. These mechanisms are characterized by dysregulation or excessive activation of the immune response, leading to acute or chronically prolonged inflammation that triggers the thrombotic and/or fibrotic process, ultimately resulting in damage to target tissues and organs. A key role is played by the interaction between cells of the innate immune system, such as neutrophils and monocytes, with tissue-resident cells, such as fibroblasts and endothelial cells. Additionally, the induction and regulation of these interactions are significantly influenced by bioactive molecular mediators, including neutrophil extracellular traps (NETs), which carry neutrophil-derived proteins/proteases that mediate their actions (e.g., MPO, tissue factor/TF), various complement system proteins (e.g., C3a, C5a), cytokines (e.g., TNF-α, IL-6), chemokines (e.g., IL-8), and growth factors (e.g., TGF-β, PDGF).The interplay between inflammation, thrombosis, and fibrosis through the innate immune system has been a field of extensive research in recent years. However, the underlying functional mechanisms involved in various diseases remain incompletely elucidated. A better understanding of the molecular and cellular mediators and pathways involved is crucial for identifying new diagnostic and/or therapeutic targets in a range of severe inflammatory diseases and complications characterized by increased morbidity and mortality, complex pathophysiology, and clinical heterogeneity. Recent studies by our team have highlighted the critical role of neutrophils and the NETs they release (NETosis) in septic and aseptic inflammation across various clinical disease models. Specifically, despite their structural similarities, research data suggest that "not all NETs are the same," as their protein composition varies in different inflammatory conditions, a fact associated with specific diseases and/or their complications. NETs and their bioactive components can determine the functional plasticity of neutrophils in the microenvironment of each disease, inducing thrombotic and/or fibrotic damage. For instance, neutrophils, through NETosis, release bioactive TF, the primary initiator of the coagulation system, promoting immunothrombosis or even collagen production by vascular endothelium. Additionally, activated neutrophils, through NET release and the proteases they carry (e.g., MPO), acquire a pro-fibrotic role by promoting fibroblast differentiation and activation towards collagen production. Another example is the release of NETs carrying bioactive IL-1β, which characterizes flare-ups of autoinflammatory diseases such as familial Mediterranean fever (FMF), Still's disease, and ulcerative colitis (UC).Taking into account the aforementioned research data, this dissertation studied representative inflammatory clinical models of immunothrombosis and immunofibrosis, aiming to propose new cellular mechanisms and potential molecular targets. The first part of this dissertation focuses on severe COVID-19. Previous studies from our department revealed a novel pathogenic mechanism in COVID-19, identifying NETosis and the complement system as key elements of SARS-CoV-2-induced immunothrombosis. Additionally, our team recently highlighted the significant role of pulmonary fibroblasts in COVID-19-related immunothrombosis, linking the inflammatory environment of the disease to the expression and activity of TF in pulmonary fibroblasts. Clinical data support that the inflammatory response induced by severe COVID-19 in lung tissue is associated with the presence of fibrotic lesions. Building on and expanding these findings, this study investigated the mechanistic relationship between the inflammation caused by severe COVID-19 and the expression of the regulatory transcription factor KLF2 in human pulmonary fibroblasts. Furthermore, the in vitro effect of therapeutic agents used in rescue therapy (COMBI) was studied. These agents target NETs (inhaled DNase), JAK-1/2 kinases (baricitinib), and IL-6 signaling (tocilizumab) in combination, aiming to assess their potential contribution to disease control. The results demonstrate reduced KLF2 expression in pulmonary fibroblasts as a key negative regulator of fibrosis and suggest molecular/cellular mediators as potential targets for addressing immunofibrosis. The study of immunothrombotic and fibrotic mechanisms in severe COVID-19 enabled the expansion of our research into other inflammatory diseases, such as Inflammatory Bowel Disease (IBD), with a focus on Crohn’s disease (CD) and ulcerative colitis (UC). The second part of this dissertation builds on this prior experience to investigate the IBD model, with an emphasis on the mechanisms linking inflammation to the development of intestinal fibrosis.CD is characterized by chronic relapsing inflammation, which, unlike UC, can lead to fibrotic intestinal strictures and fistulas. Despite advances in diagnosis and treatment, only 50% of patients achieve clinical and endoscopic remission, often requiring surgical intervention. In many cases, assessing disease activity or distinguishing between UC and CD remains challenging. The study focused on the potential mechanistic relationship between KLF2 and CD-associated immunofibrosis, as well as the differential functional plasticity of neutrophils/NETs in the two inflammatory bowel diseases. Simultaneously, the production of the IL-8 chemokine by intestinal fibroblasts sustains their reciprocal interaction with neutrophils. In addition to investigating the mechanisms underlying inflammatory and fibrotic processes, this dissertation also focuses on the development of potential new diagnostic tools to improve the clinical management of inflammatory diseases. The third part involves the development of a novel diagnostic method based on the differential protein composition of NETs in various inflammatory diseases. Previous initial findings from our laboratory suggested that the presence of IL-1β in NETs during inflammatory attacks/active phases of disease is a hallmark of IL-1β-mediated autoinflammatory diseases (AID). Given that circulating extracellular DNA is an established surrogate marker for NETs in the periphery, the method was based on an innovative “in-house” ELISA that quantitatively measures the IL-1β/extracellular DNA complex (IL-1β/cell-free DNA complex) in patient plasma. Analysis of clinically well-characterized plasma samples demonstrated that IL-1β/DNA complex levels could serve as an efficient and accurate tool for the rapid differential diagnosis of fever and acute inflammation between AID and other inflammatory conditions, such as classic autoimmune diseases, bacterial sepsis, and other infections. These preliminary results pave the way for larger, multicenter studies to further validate the diagnostic and prognostic utility of this method. Additionally, the approach could be further refined to incorporate additional protein markers [PRO(tein)/DNA ELISA], enabling its application to a broader range of inflammatory and immunothrombotic disorders where NETosis plays a significant role. Overall, this dissertation investigates molecular and cellular mechanisms linking inflammation, immunothrombosis, and fibrosis across different diseases, while also proposing NET-based diagnostic strategies to improve the clinical management of inflammatory disorders.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Natsi, Anastasia-Maria
- Νάτση, Αναστασία-Μαρία
Subjects
dc:subject × 18Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/58595